Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.17
RTIX's Cash-to-Debt is ranked lower than
89% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. RTIX: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
RTIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: 1.78 Max: 414.13
Current: 0.17
0.16
414.13
Equity-to-Asset 0.45
RTIX's Equity-to-Asset is ranked lower than
73% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. RTIX: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
RTIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.7 Max: 0.85
Current: 0.45
0.32
0.85
Piotroski F-Score: 3
Altman Z-Score: 0.76
Beneish M-Score: -2.96
WACC vs ROIC
9.18%
-5.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -5.75
RTIX's Operating Margin % is ranked lower than
60% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. RTIX: -5.75 )
Ranked among companies with meaningful Operating Margin % only.
RTIX' s Operating Margin % Range Over the Past 10 Years
Min: -76.65  Med: -0.3 Max: 8.72
Current: -5.75
-76.65
8.72
Net Margin % -5.28
RTIX's Net Margin % is ranked lower than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. RTIX: -5.28 )
Ranked among companies with meaningful Net Margin % only.
RTIX' s Net Margin % Range Over the Past 10 Years
Min: -77.87  Med: -0.6 Max: 5.28
Current: -5.28
-77.87
5.28
ROE % -10.07
RTIX's ROE % is ranked lower than
62% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. RTIX: -10.07 )
Ranked among companies with meaningful ROE % only.
RTIX' s ROE % Range Over the Past 10 Years
Min: -57.28  Med: -1.07 Max: 6.65
Current: -10.07
-57.28
6.65
ROA % -3.83
RTIX's ROA % is ranked lower than
55% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. RTIX: -3.83 )
Ranked among companies with meaningful ROA % only.
RTIX' s ROA % Range Over the Past 10 Years
Min: -44.6  Med: -0.43 Max: 3.93
Current: -3.83
-44.6
3.93
ROC (Joel Greenblatt) % -7.56
RTIX's ROC (Joel Greenblatt) % is ranked lower than
55% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. RTIX: -7.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RTIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -91.98  Med: 0.42 Max: 12.01
Current: -7.56
-91.98
12.01
3-Year Revenue Growth Rate 10.00
RTIX's 3-Year Revenue Growth Rate is ranked higher than
69% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. RTIX: 10.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RTIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.6  Med: 1.9 Max: 14.9
Current: 10
-22.6
14.9
3-Year EPS without NRI Growth Rate -3.00
RTIX's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. RTIX: -3.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RTIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.6  Med: 6.5 Max: 223.1
Current: -3
-47.6
223.1
GuruFocus has detected 7 Warning Signs with RTI Surgical Inc $RTIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RTIX's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RTIX Guru Trades in Q1 2016

Jim Simons 326,700 sh (+27.02%)
Chuck Royce 1,626,234 sh (+4.33%)
» More
Q2 2016

RTIX Guru Trades in Q2 2016

Jim Simons 388,500 sh (+18.92%)
Chuck Royce 1,003,055 sh (-38.32%)
» More
Q3 2016

RTIX Guru Trades in Q3 2016

Jim Simons 523,000 sh (+34.62%)
Chuck Royce 833,655 sh (-16.89%)
» More
Q4 2016

RTIX Guru Trades in Q4 2016

Jim Simons 674,200 sh (+28.91%)
Chuck Royce 776,655 sh (-6.84%)
» More
» Details

Insider Trades

Latest Guru Trades with RTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:AMEX:CVRS, OTCPK:XVIPF, NAS:CUTR, NAS:OBLN, NAS:TCMD, NAS:ACRX, NAS:IRIX, NAS:AXGN, OTCPK:JLFNF, NAS:NVCN, NAS:EXAC, NAS:FONR, NAS:CGNT, NAS:MSON, NAS:DRAD, NAS:ELOS, NAS:IRMD, NAS:SPNE, NYSE:IVC, NAS:EDAP » details
Traded in other countries:RT2.Germany,
Headquarter Location:USA
RTI Surgical Inc is a surgical implant company. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, dermal tissue and bovine and porcine animal tissue.

RTI Surgical Inc, formerly RTI Biologics, Inc., was incorporated in 1997 in Florida as a wholly-owned subsidiary of the University of Florida Tissue Bank. The Company process donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Company process tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufacture metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in all 50 states and in over 45 countries. Its lines of business are comprised primarily of six categories: spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental and ortho fixation. It has developed and utilized in the United States the patented BioCleanse tissue sterilization process, which is an automated, pharmaceutical grade chemical sterilization process for musculoskeletal bone and certain soft tissue. The TUTOPLAST tissue sterilization process utilizes solvent dehydration and chemical inactivation to remove blood, lipids and extraneous materials, and inactivate viruses and break down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties. DBM-based pastes and putties are sterilized through the CANCELLE SP process, which is designed to preserve protein activity. The Company's competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation ("MTF"), AlloSource, LifeCell, Inc., a subsidiary of Kinetic Concepts Inc. and LifeNet. Among its competitors in precision machined allograft are MTF, LifeNet and AlloSource. Other companies who process and distribute allograft pastes include Medtronic, AlloSource, Integra, Wright and MTF. Companies who process and distribute xenograft tissue include Synovis, LifeCell, Cook Surgical and Medtronic. The Company considers its competitors in the metal and synthetic markets to include Alphatec, Globus Medical, Inc. (Globus), NuVasive, Inc. (NuVasive) and Orthofix. The Company is subject to federal, state and foreign laws and regulations.

Ratios

vs
industry
vs
history
Forward PE Ratio 51.28
RTIX's Forward PE Ratio is ranked lower than
95% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. RTIX: 51.28 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.20
RTIX's PB Ratio is ranked higher than
64% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. RTIX: 2.20 )
Ranked among companies with meaningful PB Ratio only.
RTIX' s PB Ratio Range Over the Past 10 Years
Min: 0.27  Med: 1.27 Max: 3.17
Current: 2.2
0.27
3.17
PS Ratio 0.84
RTIX's PS Ratio is ranked higher than
85% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. RTIX: 0.84 )
Ranked among companies with meaningful PS Ratio only.
RTIX' s PS Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.19 Max: 4.34
Current: 0.84
0.54
4.34
Price-to-Operating-Cash-Flow 14.96
RTIX's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. RTIX: 14.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RTIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.57  Med: 26.4 Max: 924
Current: 14.96
3.57
924
EV-to-EBIT -22.54
RTIX's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. RTIX: -22.54 )
Ranked among companies with meaningful EV-to-EBIT only.
RTIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -341.4  Med: -0.9 Max: 542.1
Current: -22.54
-341.4
542.1
EV-to-EBITDA 505.47
RTIX's EV-to-EBITDA is ranked lower than
98% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. RTIX: 505.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
RTIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -123.4  Med: 7.9 Max: 537.65
Current: 505.47
-123.4
537.65
Current Ratio 3.06
RTIX's Current Ratio is ranked higher than
61% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. RTIX: 3.06 )
Ranked among companies with meaningful Current Ratio only.
RTIX' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 3.39 Max: 5.43
Current: 3.06
1.5
5.43
Quick Ratio 1.03
RTIX's Quick Ratio is ranked lower than
78% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. RTIX: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
RTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.55 Max: 2.98
Current: 1.03
0.92
2.98
Days Inventory 315.43
RTIX's Days Inventory is ranked lower than
86% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. RTIX: 315.43 )
Ranked among companies with meaningful Days Inventory only.
RTIX' s Days Inventory Range Over the Past 10 Years
Min: 248.06  Med: 310.14 Max: 366.78
Current: 315.43
248.06
366.78
Days Sales Outstanding 55.50
RTIX's Days Sales Outstanding is ranked higher than
69% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. RTIX: 55.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
RTIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.51  Med: 46.94 Max: 61.08
Current: 55.5
36.51
61.08
Days Payable 67.83
RTIX's Days Payable is ranked higher than
55% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. RTIX: 67.83 )
Ranked among companies with meaningful Days Payable only.
RTIX' s Days Payable Range Over the Past 10 Years
Min: 44.15  Med: 62.07 Max: 83.22
Current: 67.83
44.15
83.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
RTIX's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. RTIX: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RTIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.4  Med: -3.9 Max: -0.8
Current: -1.1
-22.4
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.78
RTIX's Price-to-Tangible-Book is ranked lower than
75% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. RTIX: 8.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RTIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 2.51 Max: 9.67
Current: 8.78
1
9.67
Price-to-Intrinsic-Value-Projected-FCF 2.31
RTIX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
52% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. RTIX: 2.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RTIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.42 Max: 20.43
Current: 2.31
0.76
20.43
Price-to-Median-PS-Value 0.71
RTIX's Price-to-Median-PS-Value is ranked higher than
79% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. RTIX: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RTIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.22 Max: 3.29
Current: 0.71
0.58
3.29
Earnings Yield (Greenblatt) % -4.43
RTIX's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. RTIX: -4.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RTIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.43  Med: 5.1 Max: 10.1
Current: -4.43
-4.43
10.1

More Statistics

Revenue (TTM) (Mil) $272.9
EPS (TTM) $ -0.31
Beta1.61
Short Percentage of Float1.99%
52-Week Range $2.50 - 4.65
Shares Outstanding (Mil)58.46

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) 0.08 0.16
EPS without NRI ($) 0.08 0.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RTIX

Headlines

Articles On GuruFocus.com
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 09 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 05 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 02 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 04 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 02 2009 

More From Other Websites
RTI Surgical reports 1Q loss Apr 27 2017
RTI Surgical® Announces 2017 First Quarter Results Apr 27 2017
RTI Surgical® Schedules 2017 First Quarter Earnings Call for April 27, 2017 Apr 20 2017
RTI Surgical® Expands Line of Matrices in International Markets Apr 18 2017
ETFs with exposure to RTI Surgical, Inc. : April 17, 2017 Apr 17 2017
RTI Surgical, Inc. :RTIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
RTI Surgical, Inc. :RTIX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
RTI Surgical, Inc. and Krensavage Partners, LP Reach Settlement Agreement Mar 15 2017
Accelerate Diagnostics (AXDX) Looks Good: Stock Up 7.5% Feb 27 2017
Edited Transcript of RTIX earnings conference call or presentation 23-Feb-17 1:30pm GMT Feb 23 2017
RTI Surgical® Announces 2016 Fourth Quarter, Full Year Results; Initiates Actions to Improve... Feb 23 2017
RTI Surgical® Schedules 2016 Fourth Quarter, Year End Earnings and Conference Call for Feb. 23,... Feb 16 2017
RTI Surgical® Makes an Inducement Grant to Camille Farhat, New Chief Executive Officer Feb 15 2017
RTI Surgical Names Camille Farhat Chief Executive Officer Jan 26 2017
RTI Surgical Extends Deadline for Nominating Directors to the Board Jan 17 2017
ETFs with exposure to RTI Surgical, Inc. : December 19, 2016 Dec 19 2016
RTI Surgical® Names Robert P. Jordheim Interim CEO Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)